Edition:
United Kingdom

Akebia Therapeutics Inc (AKBA.OQ)

AKBA.OQ on NASDAQ Stock Exchange Global Market

14.31USD
21 Feb 2018
Change (% chg)

$0.69 (+5.07%)
Prev Close
$13.62
Open
$13.75
Day's High
$14.74
Day's Low
$13.60
Volume
169,571
Avg. Vol
128,966
52-wk High
$20.25
52-wk Low
$8.60

Chart for

About

Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company's lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD). It is involved in... (more)

Overall

Beta: 1.02
Market Cap(Mil.): $894.46
Shares Outstanding(Mil.): 47.15
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Akebia Therapeutics Gives Update On Vadadustat Development Program

* AKEBIA THERAPEUTICS PROVIDES UPDATE ON VADADUSTAT DEVELOPMENT PROGRAM

12 Feb 2018

BRIEF-Akebia Therapeutics reports Q3 loss per share $0.49

* Akebia Therapeutics announces third quarter 2017 financial results

08 Nov 2017

BRIEF-Invirsa secures seed financing to develop new approach

* Invirsa secures seed financing to develop new approach to treating common infectious diseases that affect millions annually Source text for Eikon: Further company coverage:

07 Nov 2017

Insider trading suspect out of U.S. jail as judge weighs 'Jekyll & Hyde' risk

BOSTON, Oct 12 A former Akebia Therapeutics Inc employee accused of insider trading was released from jail on Thursday despite a judge's concern that the man's "Dr. Jekyll and Mr. Hyde" tendencies could lead him to violate his bail conditions.

12 Oct 2017

Ex-Akebia employee suspected of insider trading re-arrested

BOSTON A former Akebia Therapeutics Inc employee accused of insider trading was re-arrested on Friday after violating a bail condition as a prosecutor who once called him "increasingly unhinged" said he would seek the man's detention pending trial.

22 Sep 2017

Ex-Akebia employee suspected of insider trading re-arrested

BOSTON, Sept 22 A former Akebia Therapeutics Inc employee accused of insider trading was re-arrested on Friday after violating a bail condition as a prosecutor who once called him "increasingly unhinged" said he would seek the man's detention pending trial.

22 Sep 2017

Competitors

  Price Chg
Amgen, Inc. (AMGN.OQ) $182.43 -0.55
Johnson & Johnson (JNJ.N) $129.91 -0.96
Roche Holding Ltd. (ROG.S) CHF223.50 -0.40
Roche Holding Ltd. (RO.S) CHF227.60 --
FibroGen Inc (FGEN.OQ) $56.00 +1.40
AstraZeneca plc (AZN.L) 4,799.50 +77.50
Astellas Pharma Inc (4503.T) ¥1,517 +8.50
GlaxoSmithKline plc (GSK.L) 1,324.60 -0.40
Bayer AG (BAYGn.DE) €98.43 --
Bayer AG (BAYE.F) -- --

Earnings vs. Estimates